Literature DB >> 34369199

Development and Validation of a Risk Score Model for Predicting the Cardiovascular Outcomes After Breast Cancer Therapy: The CHEMO-RADIAT Score.

Do Young Kim1, Myung-Soo Park1, Jong-Chan Youn1,2, Sunki Lee1, Jae Hyuk Choi1, Mi-Hyang Jung1, Lee Su Kim3, Sung Hea Kim4, Seongwoo Han1, Kyu-Hyung Ryu1.   

Abstract

Background Cardiovascular disease is an important cause of mortality among survivors of breast cancer (BC). We developed a prediction model for major adverse cardiovascular events after BC therapy, which is based on conventional and BC treatment-related cardiovascular risk factors. Methods and Results The cohort of the study consisted of 1256 Asian female patients with BC from 4 medical centers in Korea and was randomized in a 1:1 ratio into the derivation and validation cohorts. The outcome measures comprised cardiovascular mortality, myocardial infarction, congestive heart failure, and transient ischemic attack/stroke. To correct overfitting, a penalized Cox proportional hazards regression was performed with a cross-validation approach. Number of cardiovascular diseases (myocardial infarction, peripheral artery disease, heart failure, and transient ischemic attack/stroke), number of baseline cardiovascular risk factors (hypertension, age ≥60, body mass index ≥30 kg/m2, estimated glomerular filtration rate <60 mL/min per 1.73 m2, dyslipidemia, and diabetes mellitus), radiation to the left breast, and anthracycline dose per 100 mg/m2 were included in the risk prediction model. The time-dependent C-indices at 3 and 7 years after BC diagnosis were 0.876 and 0.842, respectively, in the validation cohort. Conclusions A prediction score model, including BC treatment-related risk factors and conventional risk factors, was developed and validated to predict major adverse cardiovascular events in patients with BC. The CHEMO-RADIAT (congestive heart failure, hypertension, elderly, myocardial infarction/peripheral artery occlusive disease, obesity, renal failure, abnormal lipid profile, diabetes mellitus, irradiation of the left breast, anthracycline dose, and transient ischemic attack/stroke) score may provide overall cardiovascular risk stratification in survivors of BC and can assist physicians in multidisciplinary decision-making regarding the BC treatment.

Entities:  

Keywords:  breast cancer; major adverse cardiovascular events; multicenter cohort; prediction model; risk stratification

Year:  2021        PMID: 34369199     DOI: 10.1161/JAHA.121.021931

Source DB:  PubMed          Journal:  J Am Heart Assoc        ISSN: 2047-9980            Impact factor:   5.501


  3 in total

1.  An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline.

Authors:  Hsiang-Chun Lee; Jhih-Yuan Shih; Wei-Ting Chang; Chung-Feng Liu; Yin-Hsun Feng; Chia-Te Liao; Jhi-Joung Wang; Zhih-Cherng Chen
Journal:  Arch Toxicol       Date:  2022-07-25       Impact factor: 6.168

Review 2.  Imaging of heart disease in women: review and case presentation.

Authors:  Nidaa Mikail; Alexia Rossi; Susan Bengs; Ahmed Haider; Barbara E Stähli; Angela Portmann; Alessio Imperiale; Valerie Treyer; Alexander Meisel; Aju P Pazhenkottil; Michael Messerli; Vera Regitz-Zagrosek; Philipp A Kaufmann; Ronny R Buechel; Cathérine Gebhard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-08-17       Impact factor: 10.057

3.  Is there a window of opportunity to optimize trastuzumab cardiac monitoring?

Authors:  Bruno Henrique Rala de Paula; Maria Eduarda Teixeira Ferro Costa; Carlos Augusto Moreira de Sousa; José Bines
Journal:  World J Cardiol       Date:  2022-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.